心房颤动患者非维生素K拮抗剂口服抗凝药的停用情况
该研究连续纳入1415例房颤患者,其中439例CHA2DS2-VASc≥1且正在服用NOAC,中位随访3.6年。33.5%的患者停用原NOAC,严重不良事件导致停药者占6.4%;阿哌沙班停药时间最长,年龄为停药的独立预测因素。
要点
- 房颤患者NOAC停药率较高,中位随访3.6年达33.5%。
- 阿哌沙班停药时间较达比加群和利伐沙班更长。
- 年龄是NOAC停药的独立预测因素,女性预测严重不良事件。
核心结论
- 在整合照护门诊中,NOAC使用安全且耐受性良好。
- 阿哌沙班是否较其他NOAC耐受性更佳尚需进一步研究。
研究设计与样本
- 共1415例房颤患者,其中439例CHA2DS2-VASc≥1且正在服用NOAC,平均年龄71.9±8.7岁,女性占37%。
- 前瞻性收集基线特征、停药原因、平均停药时间及停药预测因素进行分析。
主要发现
- 中位随访3.6年(IQR=2.7-5.3),147例(33.5%)停用原NOAC,其中113例换用其他形式口服抗凝药,停药率为8.8/100患者年。
- 28例(6.4%)因严重不良事件停药,发生率为1.6事件/100患者年。
- 平均停药时间为4.9年(95%CI 4.6-5.1);阿哌沙班停药时间最长(5.1年,95%CI 4.8-5.4),达比加群为4.6年(95%CI 4.2-4.9),利伐沙班为4.5年(95%CI 3.9-5.1),两两log-rank p分别为0.002和0.025。
- 多变量分析中,年龄是原NOAC停药的独立预测因素(HR 1.03,95%CI 1.01-1.05;p=0.006)。
- 女性是严重不良事件的独立预测因素(HR 2.2,95%CI 1.04-4.64;p=0.04)。
临床怎么用
- 在整合照护门诊中处方NOAC时,应关注高龄和女性患者的停药风险及严重不良事件。
- 阿哌沙班可能具有更长的持续用药时间,但需进一步研究验证。
局限性
- 本研究为单中心真实世界队列,结果外推需谨慎。
- 阿哌沙班耐受性优势的结论尚需进一步研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterise the rate, causes and predictors of cessation of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). PATIENTS AND METHODS: Consecutive patients with AF with a long-term anticoagulation indication treated with NOACs (dabigatran, apixaban and rivaroxaban) in our centre from September 2010 through December 2016 were included. Prospectively collected data with baseline characteristics, causes of cessation, mean duration-to-cessation and predictors of cessation were analysed. RESULTS: The study comprised 1415 consecutive patients with AF, of whom 439 had a CHA2DS2-VASc≥1 and were on a NOAC. Mean age was 71.9±8.7 years and 37% were females. Over a median follow-up of 3.6 years (IQR=2.7-5.3), 147 (33.5%) patients ceased their index-NOAC (113 switched to a different form of OAC), at a rate of 8.8 per 100 patient-years. Serious adverse events warranting NOAC cessation occurred in 28 patients (6.4%) at a rate of 1.6 events per 100 patient-years. The mean duration-to-cessation was 4.9 years (95% CI 4.6 to 5.1) and apixaban had the longest duration-to-cessation with (5.1, 95% CI 4.8 to 5.4) years, compared with dabigatran (4.6, 95% CI 4.2 to 4.9) and rivaroxaban (4.5, 95% CI 3.9 to 5.1), pairwise log-rank p=0.002 and 0.025, respectively. In multivariable analyses, age was an independent predictor of index-NOAC cessation (HR 1.03, 95% CI 1.01 to 1.05; p=0.006). Female gender (HR 2.2, 95% CI 1.04 to 4.64; p=0.04) independently predicted serious adverse events. CONCLUSION: In this 'real world' cohort, NOAC use is safe and well-tolerated when prescribed in an integrated care clinic. Whether apixaban is better tolerated compared with other NOACs warrants further study.
引用
- Middeldorp ME, Gupta A, Elliott A, et al. Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Heart. 2021. PMID: 33067328. doi:10.1136/heartjnl-2020-317418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。